FAM
CRMD icon

Fulcrum Asset Management’s CorMedix CRMD Stock Holding History

Fulcrum Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.4K Buy
+5,940
New +$46.9K ﹤0.01% 565

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Fulcrum Asset Management's CRMD Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in CorMedix (CRMD) in Q2 2026: 5,940 shares worth $45.4K. The stake represents ﹤0.01% of the portfolio and ranks #565 among its holdings.

194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Fulcrum Asset Management held 5,940 shares of CorMedix worth $45.4K as of Q2 2026.
  • CorMedix was a new Fulcrum Asset Management position in Q2 2026.
  • CorMedix made up ﹤0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #565 holding.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.